Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner

Utpal B Pajvani1, Carrie J Shawber, Varman T Samuel

  • 1Department of Medicine, Columbia University, New York, New York, USA.

Nature Medicine
|August 2, 2011
PubMed

Insights

Notch signaling inhibition improves insulin sensitivity by reducing hepatic glucose production, offering a new therapeutic strategy for diabetes. This approach targets the interplay between FoxO1 and Notch pathways.

Area of Science:

  • Metabolic regulation
  • Molecular endocrinology
  • Signaling pathways

Background:

  • Transcription factor FoxO1 is a key regulator of hepatic glucose production, making it a target for diabetes treatment.
  • Notch signaling alterations are implicated in cancer, with antagonists in clinical trials.
  • The interplay between FoxO1 and Notch in metabolic regulation is largely unexplored.

Purpose of the Study:

  • To investigate the coordinated roles of FoxO1 and Notch signaling in regulating hepatic glucose metabolism.
  • To determine the therapeutic potential of modulating Notch signaling for insulin resistance and diabetes.

Main Methods:

  • Genetic manipulation including combined haploinsufficiency of FoxO1 and Notch1, and liver-specific knockout of Rbp-Jκ.
  • In vivo administration of γ-secretase inhibitors to block Notch signaling.
  • Assessment of insulin sensitivity and hepatic glucose production in mouse models of diet-induced obesity and insulin resistance.

Main Results:

  • Combined haploinsufficiency of FoxO1 and Notch1, or knockout of Rbp-Jκ, significantly improved insulin sensitivity in diet-induced insulin-resistant mice.
  • Notch1 gain-of-function exacerbated insulin resistance in a FoxO1-dependent manner and increased glucose-6-phosphatase expression.
  • Pharmacological inhibition of Notch signaling using γ-secretase inhibitors enhanced insulin sensitivity in both lean and obese mice.

Conclusions:

  • Notch signaling plays a previously unrecognized role in hepatic glucose metabolism.
  • Inhibition of Notch signaling is a promising therapeutic strategy for diabetes, partly by counteracting FoxO1-mediated hepatic glucose production.
  • Targeting the Notch pathway offers a novel approach to improve insulin sensitivity and manage metabolic dysfunction.

Related Concept Videos

Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...